000291917 001__ 291917
000291917 005__ 20241110013656.0
000291917 0247_ $$2doi$$a10.3390/nu16142251
000291917 0247_ $$2pmid$$apmid:39064694
000291917 0247_ $$2pmc$$apmc:PMC11279740
000291917 0247_ $$2altmetric$$aaltmetric:168278288
000291917 037__ $$aDKFZ-2024-01529
000291917 041__ $$aEnglish
000291917 082__ $$a610
000291917 1001_ $$0P:(DE-He78)1d6f6305a65e2f7de2c7fbffbae83780$$aSha, Sha$$b0$$eFirst author$$udkfz
000291917 245__ $$aThe Safety Profile of Vitamin D Supplements Using Real-World Data from 445,493 Participants of the UK Biobank: Slightly Higher Hypercalcemia Prevalence but Neither Increased Risks of Kidney Stones nor Atherosclerosis.
000291917 260__ $$aBasel$$bMDPI$$c2024
000291917 3367_ $$2DRIVER$$aarticle
000291917 3367_ $$2DataCite$$aOutput Types/Journal article
000291917 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1722250169_32764
000291917 3367_ $$2BibTeX$$aARTICLE
000291917 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000291917 3367_ $$00$$2EndNote$$aJournal Article
000291917 500__ $$a#EA:C070#LA:C070#LA:C120#
000291917 520__ $$aBackground: Potential calcium-related adverse events of vitamin D supplement use have not been addressed in large-scale, real-world data so far. Methods: Leveraging data from the UK Biobank, encompassing 445,493 individuals aged 40-69, we examined associations of high 25-hydroxyvitamin (25(OH)D) levels ≥ 100 nmol/L and vitamin D supplementation with hypercalcemia (serum calcium > 2.6 mmol/L), kidney stones, and atherosclerosis assessments (pulse wave arterial stiffness index and carotid intima-medial thickness). Regression models were comprehensively adjusted for 49 covariates. Results: Approximately 1.5% of the participants had high 25(OH)D levels, 4.3% regularly used vitamin D supplements, and 20.4% reported regular multivitamin use. At baseline, the hypercalcemia prevalence was 1.6%, and 1.1% was diagnosed with kidney stones during follow-up. High 25(OH)D levels were neither associated with calcium-related adverse events nor atherosclerosis assessments. Vitamin D and multivitamin supplementation were associated with an increased prevalence of hypercalcemia (odds ratios and 95% confidence intervals: 1.46 [1.32-1.62] and 1.11 [1.04-1.18], respectively) but were neither associated with atherosclerosis nor future kidney stones. Conclusions: High 25(OH)D levels observable in routine care were not associated with any adverse outcome. Vitamin D users have a slightly higher prevalence of hypercalcemia, possibly due to co-supplementation with calcium, but without a higher atherosclerosis prevalence or risk of kidney stones.
000291917 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000291917 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000291917 650_7 $$2Other$$aadverse events
000291917 650_7 $$2Other$$aatherosclerosis
000291917 650_7 $$2Other$$ahypercalcemia
000291917 650_7 $$2Other$$akidney stone risk
000291917 650_7 $$2Other$$areal-world evidence
000291917 650_7 $$2Other$$aserum 25-hydroxyvitamin D levels
000291917 650_7 $$2Other$$avitamin D supplementation
000291917 650_7 $$01406-16-2$$2NLM Chemicals$$aVitamin D
000291917 650_7 $$0A288AR3C9H$$2NLM Chemicals$$a25-hydroxyvitamin D
000291917 650_7 $$0SY7Q814VUP$$2NLM Chemicals$$aCalcium
000291917 650_2 $$2MeSH$$aHumans
000291917 650_2 $$2MeSH$$aHypercalcemia: epidemiology
000291917 650_2 $$2MeSH$$aHypercalcemia: chemically induced
000291917 650_2 $$2MeSH$$aVitamin D: analogs & derivatives
000291917 650_2 $$2MeSH$$aVitamin D: blood
000291917 650_2 $$2MeSH$$aVitamin D: administration & dosage
000291917 650_2 $$2MeSH$$aMiddle Aged
000291917 650_2 $$2MeSH$$aMale
000291917 650_2 $$2MeSH$$aFemale
000291917 650_2 $$2MeSH$$aDietary Supplements: adverse effects
000291917 650_2 $$2MeSH$$aUnited Kingdom: epidemiology
000291917 650_2 $$2MeSH$$aKidney Calculi: epidemiology
000291917 650_2 $$2MeSH$$aKidney Calculi: blood
000291917 650_2 $$2MeSH$$aAged
000291917 650_2 $$2MeSH$$aAtherosclerosis: epidemiology
000291917 650_2 $$2MeSH$$aAtherosclerosis: etiology
000291917 650_2 $$2MeSH$$aAdult
000291917 650_2 $$2MeSH$$aPrevalence
000291917 650_2 $$2MeSH$$aBiological Specimen Banks
000291917 650_2 $$2MeSH$$aRisk Factors
000291917 650_2 $$2MeSH$$aCalcium: blood
000291917 650_2 $$2MeSH$$aCalcium: administration & dosage
000291917 650_2 $$2MeSH$$aUK Biobank
000291917 7001_ $$0P:(DE-He78)32395dd61ce265f1f29942fadf07e669$$aDegen, Miriam$$b1$$udkfz
000291917 7001_ $$0P:(DE-He78)236d02bfaad255f19aa65e9cd9d63a8a$$aVlaski, Tomislav$$b2$$udkfz
000291917 7001_ $$0P:(DE-He78)79862c68074f8d78156f06f6e3c9801c$$aFan, Ziwen$$b3$$udkfz
000291917 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$eLast author$$udkfz
000291917 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b5$$eLast author$$udkfz
000291917 773__ $$0PERI:(DE-600)2518386-2$$a10.3390/nu16142251$$gVol. 16, no. 14, p. 2251 -$$n14$$p2251$$tNutrients$$v16$$x2072-6643$$y2024
000291917 8564_ $$uhttps://inrepo02.dkfz.de/record/291917/files/nutrients-16-02251-v2.pdf
000291917 8564_ $$uhttps://inrepo02.dkfz.de/record/291917/files/nutrients-16-02251-v2.pdf?subformat=pdfa$$xpdfa
000291917 909CO $$ooai:inrepo02.dkfz.de:291917$$pVDB
000291917 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1d6f6305a65e2f7de2c7fbffbae83780$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000291917 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)32395dd61ce265f1f29942fadf07e669$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000291917 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)236d02bfaad255f19aa65e9cd9d63a8a$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000291917 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79862c68074f8d78156f06f6e3c9801c$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000291917 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000291917 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000291917 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000291917 9141_ $$y2024
000291917 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNUTRIENTS : 2022$$d2023-08-23
000291917 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-23
000291917 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-23
000291917 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-23
000291917 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:01:20Z
000291917 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:01:20Z
000291917 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:01:20Z
000291917 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-04-12T15:01:20Z
000291917 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-23
000291917 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-23
000291917 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-23
000291917 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-23
000291917 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-23
000291917 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-23
000291917 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNUTRIENTS : 2022$$d2023-08-23
000291917 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-23
000291917 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-23
000291917 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000291917 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000291917 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000291917 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000291917 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000291917 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000291917 980__ $$ajournal
000291917 980__ $$aVDB
000291917 980__ $$aI:(DE-He78)C070-20160331
000291917 980__ $$aI:(DE-He78)C120-20160331
000291917 980__ $$aI:(DE-He78)HD01-20160331
000291917 980__ $$aUNRESTRICTED